C
Catriona Parker
Researcher at Monash University
Publications - 35
Citations - 1041
Catriona Parker is an academic researcher from Monash University. The author has contributed to research in topics: Medicine & Minimal residual disease. The author has an hindex of 11, co-authored 31 publications receiving 812 citations. Previous affiliations of Catriona Parker include Alfred Hospital & University of Manchester.
Papers
More filters
Journal ArticleDOI
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial
Catriona Parker,Rachel Waters,Carly Leighton,Carly Leighton,Jeremy Hancock,Rosemary Sutton,Anthony V. Moorman,Philip Ancliff,Mary Morgan,Ashish Masurekar,Nicholas Goulden,Nina Green,Tamas Revesz,Philip Darbyshire,Sharon Love,Vaskar Saha +15 more
TL;DR: As compared with idarubicin, mitoxantrone conferred a significant benefit in progression-free and overall survival in children with relapsed acute lymphobastic leukaemia, a potentially useful clinical finding that warrants further investigation.
Journal ArticleDOI
Reversing Hypoxic Cell Chemoresistance in Vitro Using Genetic and Small Molecule Approaches Targeting Hypoxia Inducible Factor-1
Louisa M. Brown,Rachel L. Cowen,Camille Debray,Amanda Eustace,Janine T. Erler,Freda C. D. Sheppard,Catriona Parker,Ian J. Stratford,Kaye J. Williams +8 more
TL;DR: The potential development of HIF-1 targeted approaches in combination with chemotherapy, where hypoxic cell resistance contributes to treatment failure, is supported.
Journal ArticleDOI
Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia
Julie Irving,Amir Enshaei,Catriona Parker,Catriona Parker,Rosemary Sutton,Roland P. Kuiper,Amy Erhorn,Lynne Minto,Nicola C. Venn,Tamara Law,Jiangyan Yu,Claire Schwab,Rosanna Davies,Elizabeth Matheson,Alysia Davies,Edwin Sonneveld,Monique L. den Boer,Sharon Love,Christine J. Harrison,Peter M. Hoogerbrugge,Tamas Revesz,Vaskar Saha,Vaskar Saha,Anthony V. Moorman +23 more
TL;DR: Screening patients at relapse for key genetic abnormalities will enable the integration of genetic and clinical risk factors to improve patient stratification and outcome and the outcome of clinical standard-risk patients with high-risk cytogenetics was equivalent to clinical high- risk patients.
Journal ArticleDOI
EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications
Claire Schwab,Sarra Ryan,Lucy Chilton,Alannah Elliott,James W. Murray,Stacey Richardson,Christopher Wragg,John Moppett,Michelle Cummins,Oliver Tunstall,Catriona Parker,Vaskar Saha,Nicholas Goulden,Ajay Vora,Anthony V. Moorman,Christine J. Harrison +15 more
TL;DR: Screening is prompted for EBF1-PDGFRB in patients entered onto the current UKALL 2011 trial for whom induction therapy failed, who did not achieve remission by day 29, or who remained MRD positive (>0.5%) at week 14.
Journal ArticleDOI
Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro.
Roben G. Gieling,Catriona Parker,Lisa A. De Costa,N Robertson,Adrian L. Harris,Ian J. Stratford,Kaye J. Williams +6 more
TL;DR: CA inhibitor acetazolamide (AZM) enhanced doxorubicin toxicity but reduced melphalan toxicity in cell lines that highly expressed CA IX under anoxic conditions, reflecting modification of passive drug uptake.